Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers developed a novel scaffold to grow breast tumors with reduced immune variability, enabling more accurate immunotherapy drug testing. The new model replicates treatment-resistant breast cancer microenvironments and predicts patient responses to therapy.
Researchers found that some painkillers and fever medications may help fight infection, while others can weaken the immune system. The review highlights the need for more studies on the impact of these medicines on infectious diseases.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.
Researchers developed a new imaging approach called VascuViz to visualize blood vessels at different spatial scales. The method enables detailed mathematical models and complementary images to clarify the role of blood flow in health and disease, advancing our understanding of tissues throughout the body.
A modeling study suggests that breast cancer overdiagnosis may occur in about 15% of screen-detected cases, rather than the estimated 30%. This could spare around 25,000 women unnecessary treatment. Researchers used data from the Breast Cancer Surveillance Consortium to estimate the rate of overdiagnosis.
Computer simulations reveal metformin's effectiveness in targeting diabetes and some cancers, but also its negative consequences for others. Researchers emphasize the need for precision medicine to individualize treatment based on patient profiles.
A new study suggests that microorganisms hindering treatment have a greater influence than those enhancing it, with around 1 year after treatment begins the gut microbiota becomes a dominant factor. The research sheds light on the interaction between the gut microbiome and cancer immunotherapy response.
Cedars-Sinai investigators discover that inhibiting RIPK2 function with drugs or CRISPR/Cas9 reduces prostate cancer metastasis in mice, offering new hope for advanced prostate cancer treatment. Targeting this protein could extend patients' lives by several years.
Scientists at the Princess Máxima Center for Pediatric Oncology discovered a new combination treatment strategy for childhood T-cell acute lymphoblastic leukemia (T-ALL) by analyzing protein activity. The study found that blocking specific proteins, such as LCK and SRC, in combination with an overactive chain reaction of INSR/IGF-1R, k...
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
Researchers at University of Cincinnati develop a new probe and imaging technique to study lysosomes, aiding in cancer and neurodegenerative disease research. The probe, known as EC Green, enables multidimensional analysis of lysosome dynamics and provides stable tracking capabilities.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
Scientists have developed a new computational tool that mimics the processes of natural selection, producing proteins for medicinal and household uses. This innovation reduces the time required for laboratory evolution from months or years to just days.
A new synthetic substance, PECS-101, has been shown to prevent neuropathic pain caused by chemotherapy while improving cancer treatment outcomes. The study, conducted in mice, found that PECS-101 had no adverse effects and did not cause dependence.
Scientists at Japan Advanced Institute of Science and Technology have created nanoengineered bacteria for photothermal cancer immunotheranostics. The synthesized nanoparticles showed powerful photothermal conversion, high biocompatibility, and excellent tumor selectivity, facilitating clear fluorescent tumor visualization.
Researchers at the University of Houston have identified a new biomarker, NPY1R, that predicts therapy outcome and has potential as a drug target in estrogen receptor-positive breast cancer. The study found that NPY1R expression is associated with favorable outcomes in Luminal A subtype breast cancer, but declines in resistant cases.
A phase 3 trial demonstrates that adding darolutamide to standard therapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer. The treatment also delays disease progression and reduces need for additional therapies.
Researchers at Tokyo University of Science have developed bionanoparticles derived from corn that selectively target and inhibit the growth of cancer cells, inducing tumor necrosis factor-α release. These findings suggest a novel, economical, and safe anti-cancer therapy approach.
A recent study found that women have a 34% higher risk of severe toxicity than men in cancer treatment, with higher risks for immunotherapy and targeted therapies. The analysis of over 20,000 patients from more than 200 clinical trials supports the idea that sex may independently modulate drug toxicity.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
Pulmonary lymphangioleiomyomatosis (LAM) is a rare cancer affecting up to 1 in 1 million women worldwide, characterized by uncontrolled tumor cell growth. Researchers aim to identify new therapeutic targets using extracellular vesicles, with the goal of developing new therapies for LAM patients.
Researchers discover that chemotherapy triggers the secretion of mucins in colorectal cancer cells, forming a physical barrier that prevents drugs from reaching their intended target. The study found potential new biomarkers for disease prognosis and a promising treatment strategy using NCX blockers like SN-6.
A new study by Virginia Commonwealth University researchers finds that triplatin is effective against triple negative breast cancer with high sulfated glycosaminoglycans (sGAG) levels. The drug accumulates inside cancer cells, causing damage and slowing tumor growth.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
The opioid crisis in the US has reached epidemic levels, with over 100,000 drug overdose deaths reported for the first time. The US Centers for Disease Control and Prevention attributes the rise to abuse of synthetic opioid fentanyl and the COVID-19 pandemic.
A genome study found significant variation in human ribosomal RNA (rRNA) genes based on geographic ancestry, particularly in the 28S rRNA segment. This discovery suggests that these variants may be important for understanding cancer development and functionally assessing their impact on ribosome functions.
A clinical trial has found selinexor to be effective in shrinking tumors in almost a third of patients with recurrent glioblastoma, an aggressive brain cancer. The treatment induced responses in certain patients and allowed some to stay on the medication for over 12 months.
A study led by Clemson University geneticist Allison Hickman has identified 11 high-priority genes associated with uterine cancer. These genes are potential targets for drug therapies, offering new hope for effective treatment options.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
A recent study led by University at Buffalo researchers found that photobiomodulation reduces inflammation, improves blood flow and heals wounds up to 19 days faster. Light therapy accelerated skin healing from cancer radiation therapy by an average of 49-42 days.
A new analysis links genetic variants associated with high blood levels of lipoprotein A to a higher risk of prostate cancer, including advanced or early-age-onset cases. The study found no significant associations for other blood lipids.
USC researchers will use $18.5 million funding to study colorectal cancer in Hispanic patients, aiming to close the gap in understanding the disease and developing effective treatments. The project aims to improve patient engagement in genomic research and develop culturally relevant educational materials.
A research team has developed a new cancer treatment that targets lymph nodes using a prodrug that selectively reacts with glutathione to release nitric oxide. In a metastasis mouse model, the mice treated with the drug showed significantly reduced weight of metastatic cancer cells and improved survival rates.
Researchers have developed a novel combination of two drugs delivered in nanoparticles that extend the survival of mice with medulloblastoma. The treatment targets the mTOR pathway and reduces off-target toxicity, making it a potential less toxic alternative to current treatments.
Scientists at MIT have developed a screening method to study protein-protein interactions, which are crucial in understanding disease mechanisms. The researchers created a synthetic molecule that binds tightly to a protein implicated in cancer metastasis, providing a potential tool for disrupting disease-causing interactions.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Four MUSC Hollings Cancer Center researchers received American Cancer Society Institutional Research Grants worth $35,000 each. The grants support promising projects that aim to push cancer care forward. Researchers are working on various innovative projects, including a digital literacy training program for community health workers an...
An international team led by the University of Ottawa has published findings on the importance of the enzyme GCN5 in maintaining muscle integrity. The study discovered that GCN5 plays a crucial role in boosting the expression of key structural proteins, notably dystrophin.
A study published in Clinical Cancer Research shows that matched targeted therapy according to ESCAT's ranking of genomic alterations significantly improves survival of cholangiocarcinoma patients. Patients with ESCAT tier I-II alterations had longer median overall survival compared to those with non-actionable alterations.
Researchers at VTC have developed a promising three-pronged approach to treating glioblastoma, a lethal brain cancer. By inhibiting two specific proteins with temozolomide, they created an effective 'triple combinational therapy' that overcame chemoresistance.
A new combination immune therapy treatment extends cancer patients' lives while reducing toxic side effects and improving their overall health. This study found that the treatment was less toxic than other drugs on the market, providing an added benefit for patients' quality of life.
Researchers identified a novel therapeutic target for multiple myeloma by discovering the Sec61 translocon's vulnerability to inhibition. This targets the translocon prevents multiple myeloma cells from producing proteins through the secretory pathway, leading to their death.
Researchers at Tufts University have found that manipulating voltage patterns in tumor cells can significantly reduce tumor cell invasion and metastasis in animal models. Using FDA-approved ion channel blockers, they were able to normalize cell voltages, decrease tumor growth, and limit the spread of cancer cells.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
Researchers at RIKEN successfully treated cancer in mice using metal catalysts that assemble anticancer drugs inside the body. The technique avoids indiscriminate tissue damage and increases cancer-inhibiting activity by 1000 times.
Researchers have revealed mechanisms by which polyps develop into colorectal cancer, setting the stage for improved surveillance utilizing precision medicine. The study found that serrated polyps derive from metaplasia, an abnormal change of cells into non-native tissue.
Scientists develop hairy cellulose nanocrystals to capture and remove excess chemotherapy drugs from the blood. The nanocrystals effectively removed over 6,000 milligrams of doxorubicin per gram, increasing DOX capture by two to three orders of magnitude compared to existing methods.
Researchers found that 48% of patients experienced complete or partial response to pembrolizumab treatment, with two-thirds experiencing clinical response. The study suggests a potential for curative intent in patients with recurrent or metastatic uterine cancer.
Researchers developed a color-coded test that quickly signals whether medical nanoparticles deliver their cargo into target cells. The tool, tested in mouse cells and living mice, assesses nanoparticle formulations on their ability to escape cellular defenses and reach the cell's interior.
A portable prostate cancer screening kit could provide early warning to populations with higher incidence of prostate cancer, particularly African American men. The test uses a test strip and reader to quantify PSA from a drop of blood in minutes, delivering results in 10-15 minutes.
A study from Weill Cornell Medicine and Cornell University reveals that targeting protein ATF4 and its related metabolic protein SIRT3 can trick lymphoma cells into starving themselves, slowing their growth.
A clinical trial will harness synthetic chimeric antigen receptor (CAR) T cells to deplete immune B cells and plasma cells producing donor-specific antibodies, aiming to achieve a compatible kidney match for patients with pre-existing antibodies. The NIH-funded study, led by Penn Medicine, intends to begin enrolling patients in 2022.
A new post-surgery approach for treating HPV-related throat cancer uses low-dose radiation and spares the majority of patients from chemotherapy. The trial found high survival rates and quality of life in patients at medium risk for recurrence.
Researchers create plan for proactively developing drug cocktails against virus families, aiming to provide effective treatments in weeks, not months. The approach prioritizes combination therapy to reduce disease spread and limit viral adaptation.
Researchers developed a model of drug resistance in melanoma, revealing mechanisms involving extrachromosomal DNA amplifications and intrachromosomal chromosomal rearrangements. The study found that different forms of DNA offer 'fitness' advantages to tumor cells under varying therapeutic conditions.
The inaugural WHO classification of childhood tumors presents a single, updated compendium of all tumor entities in childhood or adolescence, divided by organ sites. This classification incorporates traditional morphology, immunohistochemistry, and molecular characteristics to provide essential criteria for definition of tumor types.
A clinical study and register studies have failed to confirm previous findings that a medicine blocking testosterone could help against COVID-19. The researchers found no discernible signs of the drug having any beneficial effect on participants' health status.
Researchers at Houston Methodist have discovered a new combination therapy that regresses tumor growth of triple negative breast cancer and prevents the cancer from spreading. The response rate using this therapy is about 50%, compared to 25-30% with older drugs, offering new hope for patients with hard-to-treat breast cancers.